Author: SleepWorld Magazine

Home Sleep Testing (HST) Sleep Apnea

Expert Insights: Dormotech Talks with Yale’s Dr. Meir Kryger on the Changing Landscape of Sleep Testing

Dormotech shares the release of a compelling expert highlight interview featuring Dr. Meir Kryger, Emeritus Professor at Yale School of Medicine. In this exclusive discussion, Dr. Kryger, a revered figure in the sleep industry who has been involved in sleep medicine since 1974, shares his unique perspective on the transformative […]

sleep wire
Company News

The Sleep Wire 

EnsoData Raises $20M to Accelerate Commercialization of AI-powered Sleep Solutions EnsoData, an innovator in AI healthtech solutions, announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its AI-powered sleep medicine solutions, improving the sleep care pathway for, in […]

Takeda's ORZEYFUL Approved in China for Narcolepsy Type 1
Pharmacological Narcolepsy

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore.   Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]

3 Powerful Takeaways from the 2025 WUN National Summit
Narcolepsy Patient Advocacy & Awareness

The Power of WUN

Attendees traveled from near and far to join us in person and online for the 2025 Wake Up Narcolepsy National Summit in Raleigh-Durham, N.C. Hosted in a different city each year, the summit provides a place where industry professionals, clinicians, individuals with narcolepsy, and family members can come together and […]

NOCTEM Health
SleepWorld Magazine Research & Studies

NOCTEM Health

An estimated one in three adults worldwide experience symptoms of insomnia, yet only a fraction of those suffering have access to specialists trained in cognitive behavioral therapy for insomnia (CBTI)—the gold standard in treatment.1,2  This unmet need has created a major bottleneck in behavioral sleep medicine, where demand far exceeds […]

Avadel Strengthens Portfolio with Exclusive License of Valiloxybate
Pharmacological

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. (“XWPharma”) together announced today that Avadel has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a GABAB receptor agonist, for all indications, including the treatment of sleep disorders, such […]